Nevertheless, it is likely that anti-CTLA4 therapy plays a dual role by both removing pre-existing T regulatory cells and by blocking CTLA4-mediated suppression of CD4 and CD8 effector T cells; together permitting improved clearance of residual cancer cells following radiation therapy. The gene discussed is CD8A; the disease is cancer.